Codex_V5

Mutant	Gene	Type	Virus	EC50 ratio	Phenotype	Assay	Reference
E22STOP	UL27	SNP	Human betaherpesvirus 5	2.00	Low level resistance	Details	Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
W153R	UL27	SNP	Human betaherpesvirus 5	1.70	No resistance	Details	Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
L193F	UL27	SNP	Human betaherpesvirus 5	2.60	Low level resistance	Details	Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
C218del	UL27	in/del	Human betaherpesvirus 5	2.50	Low level resistance	Details	Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
R233S	UL27	SNP	Human betaherpesvirus 5			Details	Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. (Jul 2004)
R233S	UL27	SNP	Human betaherpesvirus 5	0.20	Possible hypersensitivity, no resistance	Details	Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
A269T	UL27	SNP	Human betaherpesvirus 5	2.00	Low level resistance	Details	Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
301-311del	UL27	in/del	Human betaherpesvirus 5	3.10	Intermediate level resistance	Details	Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
L335P	UL27	SNP	Human betaherpesvirus 5	23.00	High level resistance	Details	Resistance of human cytomegalovirus to D- and L-ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs. (May-Aug 2003)
G344D	UL27	SNP	Human betaherpesvirus 5	0.90	No resistance	Details	Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
V353E	UL27	SNP	Human betaherpesvirus 5	2.10	Low level resistance	Details	Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
W362R	UL27	SNP	Human betaherpesvirus 5	1.90	No resistance	Details	Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. (Jul 2004)
W362STOP	UL27	SNP	Human betaherpesvirus 5	2.20	Low level resistance	Details	Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
L426F	UL27	SNP	Human betaherpesvirus 5	2.20	Low level resistance	Details	Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
V236M	UL56	SNP	Human betaherpesvirus 5	0.12	Possible hypersensitivity, no resistance	Details	Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
D344E	UL89	SNP	Human betaherpesvirus 5	0.09	Possible hypersensitivity, no resistance	Details	Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
Y335H	UL97	SNP	Human betaherpesvirus 5	1.00	No resistance	Details	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
L337M	UL97	SNP	Human betaherpesvirus 5	3.40	Intermediate level resistance	Details	Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012)
F342S	UL97	SNP	Human betaherpesvirus 5	18.00	High level resistance	Details	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
F342Y	UL97	SNP	Human betaherpesvirus 5	4.70	Intermediate level resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
F342Y	UL97	SNP	Human betaherpesvirus 5	4.20	Intermediate level resistance	Details	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
G343A	UL97	SNP	Human betaherpesvirus 5	126.00	High level resistance	Details	Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. (Sep 2024)
V345I	UL97	SNP	Human betaherpesvirus 5	0.40	Possible hypersensitivity, no resistance	Details	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
L348V	UL97	SNP	Human betaherpesvirus 5	1.60	No resistance	Details	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
V353A	UL97	SNP	Human betaherpesvirus 5	10.00	High level resistance	Details	Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007)
K355del	UL97	in/del	Human betaherpesvirus 5	304.00	High level resistance	Details	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
V356G	UL97	SNP	Human betaherpesvirus 5	108.00	High level resistance	Details	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
E362D	UL97	SNP	Human betaherpesvirus 5	0.10	Possible hypersensitivity, no resistance	Details	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
V388M	UL97	SNP	Human betaherpesvirus 5	1.10	No resistance	Details	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
L397R	UL97	SNP	Human betaherpesvirus 5	390.00	High level resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
T409M	UL97	SNP	Human betaherpesvirus 5	78.00	High level resistance	Details	Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
T409M	UL97	SNP	Human betaherpesvirus 5	80.00	High level resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
H411Y	UL97	SNP	Human betaherpesvirus 5	15.00	High level resistance	Details	Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
H411L	UL97	SNP	Human betaherpesvirus 5	21.00-99.00	Range of values of High level resistance	Details	Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
H411N	UL97	SNP	Human betaherpesvirus 5	9.00	High level resistance	Details	Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
H411Y	UL97	SNP	Human betaherpesvirus 5	17.00	High level resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
H415Y	UL97	SNP	Human betaherpesvirus 5	0.60	No resistance	Details	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
A435V	UL97	SNP	Human betaherpesvirus 5	0.60	No resistance	Details	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
C437Y	UL97	SNP	Human betaherpesvirus 5	0.90	No resistance	Details	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
D456N	UL97	SNP	Human betaherpesvirus 5	278.00	High level resistance	Details	Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
M460I	UL97	SNP	Human betaherpesvirus 5	0.21	Possible hypersensitivity, no resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
M460V	UL97	SNP	Human betaherpesvirus 5	0.30	Possible hypersensitivity, no resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
V466M	UL97	SNP	Human betaherpesvirus 5			Details
V466G	UL97	SNP	Human betaherpesvirus 5	321.00	High level resistance	Details	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
C480F	UL97	SNP	Human betaherpesvirus 5	224.00	High level resistance	Details	Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
C480F	UL97	SNP	Human betaherpesvirus 5	210.00	High level resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C480R	UL97	SNP	Human betaherpesvirus 5	243.00	High level resistance	Details	Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
H520Q	UL97	SNP	Human betaherpesvirus 5	0.66	No resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
P521L	UL97	SNP	Human betaherpesvirus 5	428.00	High level resistance	Details	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
C592G	UL97	SNP	Human betaherpesvirus 5	0.78	No resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
A594P	UL97	SNP	Human betaherpesvirus 5	1.60	No resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
A594T	UL97	SNP	Human betaherpesvirus 5	0.73	No resistance	Details	Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997)
A594V	UL97	SNP	Human betaherpesvirus 5	1.90	No resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595F	UL97	SNP	Human betaherpesvirus 5	1.30	No resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595S	UL97	SNP	Human betaherpesvirus 5	1.30	No resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595W	UL97	SNP	Human betaherpesvirus 5	1.20	No resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C603W	UL97	SNP	Human betaherpesvirus 5	1.20	No resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C603Y	UL97	SNP	Human betaherpesvirus 5	0.89	No resistance	Details	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
Y617del	UL97	in/del	Human betaherpesvirus 5	372.00	High level resistance	Details	Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)